Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech
2.4.2024 17:00:00 EEST | Business Wire | Press release
Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech. The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402275595/en/
Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)
The jury, made up of over 70 scientific, institutional, political, industrial, and financial experts, awarded companies in the French Health-Tech industry that stood out for their creativity, imagination, and dynamism over the past two years. This is a great recognition from the French health ecosystem. (France Biotech Press Release)
This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before. (Recording pitch)
"On behalf of the whole team, we thank all the jury members for this great distinction, as well as France Biotech for organizing this ceremony and for their crucial role as coordinator of the French health innovation ecosystem. Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients." declares Paul BRAVETTI, CEO of Brenus Pharma.
About Brenus Pharma :
Brenus Pharma develops first-in-class proteomic-driven cell immunotherapies focused on tumor antigens for the treatment of solid tumors. Brenus has developed the STC platform (Stimulated Tumor Cells), a technological platform that mimics relapse conditions and allows the education of the patient's immune system to fight the resistance mechanisms of tumor cells.
https://www.brenus-pharma.com/ | Linkedin
About France Biotech
France Biotech, founded in 1997, is an independent association that brings together innovation entrepreneurs in healthcare and their expert partners. As a facilitator of the healthcare innovation ecosystem and a privileged interlocutor with public authorities in France and Europe, France Biotech contributes to addressing the challenges of the HealthTech sector (company financing, innovation taxation, regulatory issues, and market access, etc.) and proposing concrete solutions in terms of competitiveness and attractiveness through its committees and working groups. This is to help start-ups and SMEs in this sector to become successful international companies capable of quickly designing and developing new innovations and ultimately making them accessible to patients. France Biotech is housed at the PariSanté Campus. http://www.france-biotech.fr/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402275595/en/
Contact information
Press contact: Florence Portejoie - FP2COM | fportejoie@fp2com.fr | (+33) 06 07 76 82 83
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Brings Mobile-First Monetization Expertise to Gamesforum Barcelona 2026, Where Europe's Mobile Gaming Leaders Gather to Solve the Industry's Toughest Growth Challenges9.2.2026 21:30:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Gamesforum Barcelona 2026, taking place Feb.10-11 at the InterContinental Hotel in Barcelona. This event brings together Europe's sharpest minds in mobile gaming for practical, data-driven sessions focused on what actually works in today's hypercompetitive mobile landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209301026/en/ (Graphic: Xsolla) With over 600 professionals from Europe's top publishers, ad networks, and studios in attendance, Gamesforum Barcelona has earned its reputation as the place where mobile gaming's most pressing problems get solved: How do you scale profitably? How do you retain players in saturated markets? How do you monetize without alienating your audience? "Gamesforum Barcelona represents everything we value about the European mobile gaming commu
Beast Industries Acquires Step, Expanding its Platform to Include Financial Services9.2.2026 19:30:00 EET | Press release
Beast Industries, the largest and most innovative creator based platform in the world, today announced the acquisition of Step, a financial technology company dedicated to making financial literacy and money management accessible to all. This acquisition marks a significant milestone for Beast Industries, bringing together Step's robust technology platform and full-stack fintech team with Beast Industries’ extensive audience reach and proven track record in philanthropic initiatives. Together, the combined organization will deliver innovative solutions that make financial wellness achievable for people at every step of their life journey. "Financial health is fundamental to overall wellbeing, yet too many people lack access to the tools and knowledge they need to build financial security," said Jeff Housenbold, CEO of Beast Industries. "This acquisition positions us to meet our audiences where they are, with practical, technology-driven solutions that can transform their financial futu
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 16:26:00 EET | Press release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at an adjusted PBR of 0.40x, representing a severe 60% discount to its Comprehensive Equity under IFRS17. Align Partners identifies inefficient capital allocation and a lack of independent governance oversight as primary drivers of this persistent undervaluation. The letter notes that DBI’s Return on Required Capital (ROR) of 21.2% significantly lags behind domestic and global peers, reflecting a historical focus on top-line growth over risk-adjusted profitability. This is exacerbated by a passive payout policy and
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 14:00:00 EET | Press release
Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/en/ “You can now potentially study intracellular target engagement for any protein in live cells,” says M
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 14:00:00 EET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom